Controlled substances; provide for automatic scheduling of certain substance if federal scheduling occurs.

SB 2056 automatically adds to Mississippi's controlled substances schedules any psilocybin-based pharmaceutical product approved by the U.S. Food and Drug Administration (FDA) and scheduled by the U.S. Drug Enforcement Administration (DEA). This applies directly to pharmaceutical companies developing such products and state law enforcement handling them under existing penalties. The bill requires the state to mirror federal scheduling immediately upon federal action, with the automatic status lasting until the next legislative session or until state law is amended. It also updates Section 41-29-111 to remove outdated references to pandemic-related provisions. The bill does not change Mississippi's scheduling process for substances not federally scheduled.